skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Renovascular and renoprotective properties of telmisartan: clinical utility

Review

(2224) Views  (1057) Full article downloads

Authors: Marco Ladino, Ivonne Hernandez Schulman

Published Date March 2010 Volume 2010:3 Pages 33 - 38
DOI: http://dx.doi.org/10.2147/IJNRD.S7033

Marco Ladino, Ivonne Hernandez Schulman

Nephrology-Hypertension Section, Veterans Affairs Medical Center and Division of Nephrology and Hypertension and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA

Abstract: Chronic kidney disease (CKD) affects approximately 26 million adults in the United States and millions of others are at increased risk. Type 2 diabetes and hypertension are the two main causes of CKD. Blood pressure control is critical to slow the progression of CKD. Despite adequate control, however, patients continue to progress to end-stage renal disease. Angiotensin receptor blockers (ARBs) are commonly used in the management of hypertension and CKD and have been shown to exert renoprotective effects that are in addition to, but independent of, blood pressure lowering. Telmisartan is a long-acting ARB with pharmacological properties beyond blockade of the angiotensin II type 1 receptor, including activation of the peroxisome proliferator activated receptor-γ (PPAR-γ). This article reviews the beneficial renal and vascular protective effects of telmisartan.

Keywords: kidney diseases, hypertension, vascular diseases, angiotensin II receptor, PPAR-γ








Readers of this article also read:

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
Expression of eNOS in kidneys from hypertensive patients
Nephrolithiasis-induced end stage renal disease
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Update on the diagnosis and management of acute kidney injury
Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio